Search company, investor...

Proteome Systems

About Proteome Systems

Tyrian Diagnostics is a biotechnology company that specialises in the discovery of biomarkers of disease and in diagnostic test development. The company are building a strong intellectual property portfolio to develop a pipeline of diagnostic products and establishing commercial partnerships to maximise market share and revenue generation from these products. One key avenue for commercialisation is the application of biomarkers to the company's point of need test platform, DiagnostIQTM.

Headquarters Location

35-41 Waterloo Road



Missing: Proteome Systems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Proteome Systems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Proteome Systems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Proteome Systems is included in 1 Expert Collection, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

2,594 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Proteome Systems Patents

Proteome Systems has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Software testing, Visual novels, Seinen manga, Biotechnology, Eroge


Application Date


Grant Date



Related Topics

Software testing, Visual novels, Seinen manga, Biotechnology, Eroge



Latest Proteome Systems News

Tyrian Diagnostics Ltd TDX Financial and Strategic SWOT Analysis Review Report Updated 07082017 Prices from USD $300

Sep 11, 2017

Summary Tyrian Diagnostics Ltd Tyrian Diagnostics formerly Proteome Systems Ltd is a medical equipment company that manufactures, and markets diagnostics for clinical and nonclinical applications. The company discovers and validates novel biomarkers for tuberculosis . It has developed a proprietary point of care diagnostics platform such as diagnostiQTM. Tyrian also develops various solutions for proteomics research. The company's technology comprises small disposable plastic capsule and a USBdriven reader machine. It distributes its product through partnerships with various marketing and distribution companies. Tyrian Diagnostics is headquartered in Sydney, New South Wales, Australia. This comprehensive SWOT profile of Tyrian Diagnostics Ltd provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Tyrian Diagnostics Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends. The profile contains critical company information including*, x000D x000D Corporate strategy Analyst's summarization of the company's business strategy.x000D SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D Company history Progression of key events associated with the company.x000D Major products and services A list of major products, services and brands of the company.x000D Key competitors A list of key competitors to the company.x000D Key employees A list of the key executives of the company.x000D Executive biographies A brief summary of the executives' employment history.x000D Key operational heads A list of personnel heading key departments/functions.x000D Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D Key manufacturing facilities A list of key manufacturing facilities of the company.x000D Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D x000D Key benefits of buying this profile include,x000D x000D You get detailed information about the company and its operations to identify potential customers and suppliers.x000D The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D x000D Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D x000D Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D x000D Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D x000D Gain key insights into the company for academic or business research.x000D Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Related Biotechnology, Pharmaceutical and Healthcare News

Proteome Systems Frequently Asked Questions (FAQ)

  • Who are Proteome Systems's competitors?

    Competitors of Proteome Systems include Oligomerix, Fujirebio, MOgene LC, NGM Biopharmaceuticals, Dyax and 13 more.

Compare Proteome Systems to Competitors


CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.

CELLective Dx Corporation

CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.


RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.


Onconix, Inc. is an intellectual property, biotechnology company focused on identifying and marketing diagnostic technologies from various research settings, which have undergone peer review. Currently, Onconix has exclusive rights to market and develop promising new tests for cervical cancer.

Diagnostic Technologies

Diagnostic Technologies Ltd. (DTL) is a medical diagnostic and biotechnology company at the forefront of placental protein molecular biology and biochemistry. The company aims to become a major player in managing high risk pregnancies by commercialising a technology platform of versatile biotechnology products for detecting and managing at risk mothers for intrauterine growth restriction, preeclampsia and pre-term delivery. The company focuses on the development of diagnostic tools to aid in the assessment of high-risk pregnancies. In particular, the technology platform focuses on pregnancy related proteomics and genomics to produce specific and sensitive testing kits for the detection of high risk and problem pregnancies.


Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.